Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in studies from Oxford and Washington Universities
One of only two authorised antibody therapies showing activity against Omicron and all other variants of concern in these studies Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retains neutralisation activity against the Omicron SARS-CoV-2 variant (B.1.1.529), according to new authentic ‘live’ virus neutralisation data from both University College Oxford, UK and Washington University School of Medicine, St. Louis, US. The